NASDAQ$NKTR
Nektar Therapeutics · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Nektar Therapeutics reported financial results for the first quarter ended March 31, 2023.
Nektar Therapeutics reported a revenue of $21.6 million for Q1 2023, compared to $24.8 million in Q1 2022. The net loss for the quarter was $137.0 million, or $0.73 loss per share, as compared to a net loss of $90.4 million, or $0.49 loss per share, in Q1 2022. Cash and investments in marketable securities were $456.8 million at the end of the quarter.
- Nektar regained full rights to rezpegaldesleukin and is progressing towards initiating a Phase 2b study in atopic dermatitis.
- The company is focusing on immunology to bring potential therapies to patients and create shareholder value.
- Nektar is advancing its immunology research pipeline with the goal of advancing a new IND candidate next year.
- Cash and investments in marketable securities are expected to support strategic development activities and operations into at least the middle of 2026.
Headline financials
Revenue & EPS history
Nektar · Revenue · Quarterly
$21.6M
Forward guidance
This press release contains forward-looking statements regarding the therapeutic potential of rezpegaldesleukin and other drug candidates, the timing for filing a new IND, expectations regarding the 2023 cost restructuring plan, and the expected working capital and cash runway.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+0.7%
Avg return
Earnings day
+1.5%
Avg return
5 days after
-3.8%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+24.8%
Q3 2017
Best reaction
-27.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -7.9% | -32.6% | |
| Q4 2025 | +4.0% | +4.0% | +10.1% | |
| Q3 2025 | +1.9% | +4.6% | +3.2% | |
| Q1 2025 | -4.1% | +16.1% | +8.1% | |
| Q4 2024 | -0.6% | +7.3% | -24.4% | |
| Q3 2024 | +0.7% | -5.8% | -26.6% | |
| Q2 2024 | -5.9% | -2.5% | -5.1% | |
| Q1 2024 | +7.3% | +7.9% | -23.2% | |
| Q4 2023 | +13.3% | +16.7% | +33.3% | |
| Q3 2023 | -5.6% | -15.1% | -3.8% | |
| Q2 2023 | -10.8% | -8.8% | -42.2% | |
| Q1 2023 | -2.6% | -5.2% | -22.1% | |
| Q4 2022 | +8.6% | +12.9% | -54.0% | |
| Q3 2022 | +3.6% | +4.1% | -16.2% | |
| Q2 2022 | +9.2% | +5.4% | -10.3% | |
| Q1 2022 | -6.7% | -17.0% | -22.1% | |
| Q4 2021 | +10.0% | +5.2% | -44.2% | |
| Q3 2021 | -21.0% | -18.8% | -36.4% | |
| Q2 2021 | +1.0% | -4.0% | +1.6% | |
| Q1 2021 | +7.6% | +3.3% | -8.3% | |
| Q4 2020 | -0.4% | +4.3% | -12.2% | |
| Q3 2020 | +2.7% | -0.8% | +2.5% | |
| Q2 2020 | +0.5% | -6.2% | -13.0% | |
| Q1 2020 | +6.3% | +11.3% | +14.0% | |
| Q4 2019 | -2.8% | -9.2% | -19.5% | |
| Q3 2019 | +0.9% | +13.2% | +10.3% | |
| Q2 2019 | -27.4% | -34.5% | -40.9% | |
| Q1 2019 | +10.5% | +1.7% | +2.9% | |
| Q4 2018 | -7.1% | -6.4% | -18.1% | |
| Q3 2018 | -2.1% | +2.5% | +2.5% | |
| Q2 2018 | +8.7% | +8.6% | +19.0% | |
| Q1 2018 | +2.1% | +7.2% | -30.4% | |
| Q4 2017 | +18.8% | +13.3% | +22.8% | |
| Q3 2017 | +24.8% | +33.9% | +125.8% | |
| Q2 2017 | -7.8% | -9.8% | +11.0% | |
| Q1 2017 | +5.8% | +9.9% | +4.1% | |
| Q4 2016 | +13.1% | +9.9% | +79.4% | |
| Q3 2016 | -1.1% | +5.1% | -0.6% | |
| Q2 2016 | +1.6% | +0.5% | +7.4% | |
| Q1 2016 | -12.3% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | -5.6% | — | — | |
| Q1 2015 | +13.3% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | -1.8% | — | — | |
| Q2 2014 | +7.4% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +15.8% | — | — | |
| Q2 2013 | +11.9% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | +1.6% | — | — | |
| Q3 2012 | -14.1% | — | — | |
| Q2 2012 | +0.6% | — | — | |
| Q1 2012 | -1.0% | — | — | |
| Q4 2011 | +9.5% | — | — | |
| Q3 2011 | -1.5% | — | — | |
| Q2 2011 | -5.4% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q4 2010 | -4.9% | — | — | |
| Q3 2010 | -4.8% | — | — | |
| Q2 2010 | -2.2% | — | — | |
| Q1 2010 | -10.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro